29.7 C
Beirut
Monday, July 26, 2021
- Advertisement -

Pfizer, BioNTech to seek authorization for COVID booster shot as Delta variant spreads

Must read

Pfizer (PFE.N)and partner BioNTech (22UAy.DE) plan to ask U.S. and European regulators within weeks to authorize a booster dose of its COVID-19 vaccine, based on evidence of greater risk of infection six months after inoculation and the spread of the highly contagious Delta variant.

The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said, however, in a joint statement that Americans who have been fully vaccinated do not need a booster COVID-19 shot at this time.

The European Medicines Agency (EMA) said it was too early to determine whether more than the two shots currently required would be called for, saying it was confident that the established regimen was sufficient. read more 

Some scientists have also questioned the need for booster shots.

Pfizer’s chief scientific officer, Mikael Dolsten, said the recently reported dip in the vaccine’s effectiveness in Israel was mostly due to infections in people who had been vaccinated in January or February. The country’s health ministry said vaccine effectiveness in preventing both infection and symptomatic disease fell to 64% in June. read more 

“The Pfizer vaccine is highly active against the Delta variant,” Dolsten said in an interview. But after six months, he said, “they’re likely is the risk of reinfection as antibodies, as predicted, wane.” Data would be submitted to the FDA within the next month, he added.

Pfizer did not release the full set of Israeli data on Thursday but said it would be published soon.

“It’s a small data set, but I think the trend is accurate: Six months out, given that Delta is the most contagious variant we have seen, it can cause infections and mild disease,” Dolsten said.

In their joint statement, the FDA and CDC said: “We are prepared for booster doses if and when the science demonstrates that they are needed.”

Pfizer’s own data from the United States showed an erosion of the vaccine’s efficacy to the mid-80s after six months, Dolsten said, against the variants circulating there in the spring.

He stressed that data from Israel and Britain suggests that even with waning antibody levels, the vaccine remains around 95% effective against severe disease.

Initially devised by Germany’s BioNTech, the vaccine showed 95% efficacy in preventing symptomatic COVID-19 in a clinical trial the companies ran last year. – Reuters

SourceNNA
- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article

- Advertisement -spot_img